JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
resistant
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 R947Q
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R938E
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R938E in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 R947Q
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R947Q
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R947Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 E1028K
|
hematologic cancer
|
resistant
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and E1028K was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and Y931C was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R938E
|
hematologic cancer
|
resistant
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R938E was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R947Q
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R947Q was resistant to Lestaurtinib (CEP-701) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 E1028K
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and E1028K in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 E1028K
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and E1028K was resistant to Lestaurtinib (CEP-701) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
sensitive
|
CHZ868
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CHZ868 inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 E1028K
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F and E1028K in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R947Q
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R947Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R947Q
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R947Q was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H
|
hematologic cancer
|
sensitive
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R938E
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R938E in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H JAK2 L983F
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L902Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 R938E
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and R938E in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and L983F was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and L902Q was resistant to Lestaurtinib (CEP-701) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
decreased response
|
CHZ868
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and Y931C was less sensitive to CHZ868 treatment than cells expressing JAK2 V617F alone in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H JAK2 L983F
|
hematologic cancer
|
sensitive
|
Tanespimycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L902Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
CHZ868
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CHZ868 inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Y931C
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and Y931C was resistant to Lestaurtinib (CEP-701) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R938E
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R938E was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 E1028K
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and E1028K was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 R947Q
|
hematologic cancer
|
sensitive
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 E1028K
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and E1028K in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H JAK2 L983F
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H JAK2 L983F
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L983F, and Q959H was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R938E
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R938E was resistant to Lestaurtinib (CEP-701) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
sensitive
|
CHZ868
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CHZ868 inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L902Q in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 R947Q
|
hematologic cancer
|
resistant
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F, L902Q, and R947Q was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 Q959H JAK2 L983F
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 E1028K
|
hematologic cancer
|
sensitive
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and E1028K in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L983F
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q JAK2 E1028K
|
hematologic cancer
|
sensitive
|
Geldanamycin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and E1028K in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inrebic (fedratinib) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
resistant
|
Fedratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and L902Q was resistant to Inrebic (fedratinib) in culture (PMID: 39091915).
|
39091915
|
JAK2 V617F JAK2 L902Q
|
hematologic cancer
|
resistant
|
Ruxolitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a cell line expressing JAK2 V617F and L902Q was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915).
|
39091915
|